Kai Lay Esther Peh
A5038116671- Phagocytosis and Immune Regulation
- Cancer, Hypoxia, and Metabolism
- Pancreatic and Hepatic Oncology Research
- Cancer Research and Treatments
- Cancer Mechanisms and Therapy
- Glaucoma and retinal disorders
- Cancer, Lipids, and Metabolism
- Microtubule and mitosis dynamics
- Cancer-related Molecular Pathways
- Neuroendocrine Tumor Research Advances
- CRISPR and Genetic Engineering
- RNA regulation and disease
- Retinal Diseases and Treatments
- Epigenetics and DNA Methylation
- Retinopathy of Prematurity Studies
- Cytomegalovirus and herpesvirus research
Bioprocessing Technology Institute
2019-2023
Agency for Science, Technology and Research
2019-2023
Cell state transitions control the functional behavior of cancer cells. Epithelial-to-mesenchymal transition (EMT) confers stem cell-like properties, enhanced tumorigenicity and drug resistance to tumor cells, while mesenchymal-epithelial (MET) reverses these phenotypes. Using high-throughput chemical library screens, retinoids are found be potent promoters MET that inhibit in basal-like breast cancer. defined by reprogramming lipid metabolism. Retinoids bind cognate nuclear receptors, which...
<h3>Importance</h3> Exfoliation syndrome is a systemic disorder characterized by progressive accumulation of abnormal fibrillar protein aggregates manifesting clinically in the anterior chamber eye. This most commonly known cause glaucoma and major irreversible blindness. <h3>Objective</h3> To determine if exfoliation associated with rare, protein-changing variants predicted to impair function. <h3>Design, Setting, Participants</h3> A 2-stage, case-control, whole-exome sequencing association...
AXL is a receptor tyrosine kinase that often overexpressed in cancers. It contributes to pathophysiology cancer progression and therapeutic resistance, making it an emerging target. The first-in-class inhibitor bemcentinib (R428/BGB324) has been granted fast track designation by the U.S. Food Drug Administration (FDA) STK11-mutated advanced metastatic non-small cell lung was also reported show selective sensitivity towards ovarian cancers (OC) with Mesenchymal molecular subtype. In this...
Abstract AXL is a receptor tyrosine kinase that often overexpressed in cancers. It contributes to pathophysiology cancer progression and therapeutic resistance, making it an emerging target. The first-in-class inhibitor bemcentinib (R428/BGB324) was approved for treatment of acute myeloid leukaemia also reported show selective sensitivity towards ovarian cancers (OC) with Mesenchymal molecular subtype. In this study, we further explored AXL’s role mediating DNA damage responses by using OC...